Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

14 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Eligibility Lung Cancer NCT02225405

- 18/11/2021 - 1 Formulier, 2 Itemgroepen, 27 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC); ODM derived from: https://clinicaltrials.gov/show/NCT02225405

Eligibility Prostate Cancer NCT02269982

- 01/10/2015 - 1 Formulier, 2 Itemgroepen, 20 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) (PCF); ODM derived from: https://clinicaltrials.gov/show/NCT02269982

Eligibility Prostate Cancer NCT02181192

- 29/09/2015 - 1 Formulier, 2 Itemgroepen, 14 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Point in Time of Radiotherapy for Patients With Biochemical Recurrent Prostate Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02181192

Eligibility Breast Neoplasms NCT00046514

- 04/06/2016 - 1 Formulier, 1 Itemgroep, 11 Data-elementen, 1 Taal
Itemgroep: Criteria
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00046514

Eligibility Neoadjuvant Operable Breast Cancer NCT02400567

- 25/09/2015 - 1 Formulier, 2 Itemgroepen, 33 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women; ODM derived from: https://clinicaltrials.gov/show/NCT02400567

Oral GW786034 treatment for ovarian cancer NCT00281632 - Additional Forms

- 03/06/2018 - 1 Formulier, 24 Itemgroepen, 95 Data-elementen, 1 Taal
Itemgroepen: Header, investigational product discontinuation, PGx-Pharmacogenetic Research, Concomitant Medications, If Yes to Concominant Medication, Non-serious adverse events, Non-serious adverse events, Serious adverse event, Serious adverse events description, Seriousness, Document section Demography data, SECTION 4, Section 5, Relevant Medical Conditions, Document section Risk factors, Document section Concomitant Medications, Drug Details, Assessments, Document section, Pregnancy information, Death, Study Conclusion, Investigator comment log, Investigators Signature
Study ID: 104450 Clinical Study ID: VEG104450 Study Title: This study is a non-randomized, open-label, multi-center Phase II study of GW786034 to evaluate the administration of oral GW786034 in subjects with ovarian cancer. Clinicaltrials.gov Identifier: NCT00281632 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib Trade Name: Votrient Study Indication: Neoplasms, Ovarian CRF Pages: 722-853

Eligibility Neutropenia in Breast Cancer NCT01079676

- 11/11/2020 - 1 Formulier, 2 Itemgroepen, 15 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
A Non-inferiority Study Comparing Two Filgrastim Preparations in Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01079676

Eligibility Vulvodynia NCT01539317

- 30/09/2021 - 1 Formulier, 2 Itemgroepen, 18 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Therapy to Prevent Sexual Pain in Breast Cancer Survivors; ODM derived from: https://clinicaltrials.gov/show/NCT01539317

Cisplatin and Topotecan Recurrent or Persistent Carcinoma of the Cervix - 103369 - Pre-Treatment Summary Sheet

- 14/03/2019 - 1 Formulier, 5 Itemgroepen, 41 Data-elementen, 1 Taal
Itemgroepen: Administrative data, Physical Examination, Laboratory Findings, Measurable Mass, Performance Grade
Study ID: 103369 Clinical Study ID: 103369 Study Title: A Randomized Phase III Study of Cisplatin Versus Cisplatin plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: Topotecan Study Indication: Cancer 

Cisplatin and Topotecan Recurrent or Persistent Carcinoma of the Cervix - 103369 - Quality of Life

- 15/03/2019 - 1 Formulier, 9 Itemgroepen, 62 Data-elementen, 1 Taal
Itemgroepen: Administrative data, Physical well-being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Additional Concerns, Brief Pain Inventory, BRIEF PAIN INVENTORY, Pain Interference
Study ID: 103369 Clinical Study ID: 103369 Study Title: A Randomized Phase III Study of Cisplatin Versus Cisplatin plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: Topotecan Study Indication: Cancer 

Cisplatin and Topotecan Recurrent on Persistent Carcinoma of the Cervix - 103369 - Initial On Study Form

- 14/03/2019 - 1 Formulier, 5 Itemgroepen, 47 Data-elementen, 1 Taal
Itemgroepen: Administrative data, Tracking Informaion, Demographic Information, Disease Information, Cancer Therapy
Study ID: 103369 Clinical Study ID: 103369 Study Title: A Randomized Phase III Study of Cisplatin Versus Cisplatin plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: Topotecan Study Indication: Cancer 

Cisplatin and Topotecan Recurrent or Persistent Carcinoma of the Cervix - 103369 - Treatment Completion Form

- 14/03/2019 - 1 Formulier, 10 Itemgroepen, 39 Data-elementen, 1 Taal
Itemgroepen: Administrative data, Treatment Completion, Tumor Measurements, Best Tumor Response, Follow-Up Form, Disease Follow-Up Status, Notice of New Primary, Long Term Adverse Events, Adverse Events details, Additional Cancer Therapy
Study ID: 103369 Clinical Study ID: 103369 Study Title: A Randomized Phase III Study of Cisplatin Versus Cisplatin plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: Topotecan Study Indication: Cancer 

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial